Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)
BARCELONA, Spain--(BUSINESS WIRE)--In 2021 the pharmaceutic company Ferrer invested 61,4% of its net profits in social and environmental causes, as part of its purpose to make a positive impact on society. As the company’s Sustainability Report states, Ferrer reinvested the major part of its profits in several projects aimed at fostering equal opportunities for people in a vulnerable situation, as well as projects aimed at protecting the planet. In this way, Ferrer materialized its purpose to make a positive impact. And the number of net profits invested represent a 53,2% rise in comparison to 2020.
Barcelona, 26 April, 2022.- Ferrer has joined the Barcelona City Council, EADA Business School and B Lab Spain in the Barcelona+B initiative, a pioneering project in Spain to promote social and business transformation and promote a more prosperous, sustainable and inclusive city.
During Ferrer Spain's III Annual Meeting, more than 400 people have participated in a social initiative in Cartaya (Huelva, Spain), collaborating in several activities aimed at promoting equal opportunities and the protection of the environment. The participants apread out among various facilities in the municipality and, together with the residents of the town, carried out tasks to improve and transform different spaces of social interest in the area, some of them very badly affected by the DANA storm in September.
Barcelona, ??May 11, 2022 – For the fourth consecutive year, the open innovation program in digital health, Ferrer 4 Future, launches a new challenge to the entrepreneurial ecosystem of digital health start-ups. On this occasion, the initiative aims to find a solution to improve clinical research on Cyclic Vomiting Syndrome (CVS).
At Ferrer, we are taking action in Costa Rica to fight for a liveable planet. As another demonstration of our commitment to making a positive impact in society, in June 2021, we started a program in Costa Rica to recover expired or disused medicines that were in doctors' offices, in presentation of a medical sample.
Coinciding with World Pulmonary Hypertension (PH) Day, which is celebrated every May 5th, Ferrer, with the support of the European Pulmonary Hypertension Association - PHA Europe, launches the PHantasticals awareness campaign, an initiative that seeks to raise public awareness about rare and chronic pathologies in the area of pulmonary vascular and interstitial lung diseases and, later, also in the field of neurological disorders.
Ferrer is conducting a phase 3 trial to evaluate the safety and efficacy of the investigational medicinal product FNP122 in the treatment of amyotrophic lateral sclerosis (ALS).
Barcelona, 24 February. In the run up to Rare Disease Day, which is held on 28 February, international pharmaceutical company, Ferrer, has strengthened its focus on pulmonary vascular and interstitial lung diseases, as well as neurological disorders, by announcing today the signing of a distribution agreement with United Therapeutics Corporation (Nasdaq: UTHR) for Tyvaso® (treprostinil) inhalation solution – a pharmaceutical drug-device combination product for the treatment of WHO Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD)4.
Barcelona, January 26, 2022.- Ferrer, the international pharmaceutical laboratory based in Barcelona, has become a B Corp company thanks to its positive impact in society and on the planet. The company has exceeded global B Corp standards in terms of social and environment performance, transparency and corporate responsibility in all the territories in which it has a direct presence. With the completion of the certification process, Ferrer is the first Spanish pharmaceutical company to become part of the international B Corp community, the group of companies that aim to build a more inclusive and sustainable economy.